Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms)
- Authors: Gusev Е.I.1,2, Demina Т.L.3,2, Boiko А.N.1,2, Buglak А.V.1,2, Belyaeva I.А.1,2, Smirnova N.F.1,2, Alekseeva Т.G.1,2, Pashchenkov М.V.1,2, Skurkovich В.1,2, Kelly D.1,2, Skurkovic S.V.1,2
 - 
							Affiliations: 
							
- Russian State Medical University
 - ABC Labs
 - Российский государственный медицинский университет
 
 - Issue: Vol XXIX, No 1-2 (1997)
 - Pages: 55-58
 - Section: Articles
 - URL: https://bakhtiniada.ru/1027-4898/article/view/79894
 - DOI: https://doi.org/10.17816/nb79894
 - ID: 79894
 
Cite item
Full Text
Abstract
For treating active forms of secondarily-progressing multiple sclerosis a preliminary clinical trial was performed by two courses: antibody-to-cytokine course (γINT, αINT and TNFα) and cyclosporin А-course (sandimmun). Data of preliminary test of antibodies to cytokines evidence to possibility of performing further clinical trials "antibodies to γINT and to TNFα (to a lesser degree)" during active forms of progressive MS. Were obtained the results, evidencing to a possible use of sandimmun in constantly progressive forms of secondarily progressing disease, when favourable clinical effect coincided with supression of cytokine IL-2 production and lowering of activeness of immunocytes.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Е. I. Gusev
Russian State Medical University; ABC Labs
							Author for correspondence.
							Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
Т. L. Demina
Российский государственный медицинский университет; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Москва; Роквил, США						
А. N. Boiko
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
А. V. Buglak
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
I. А. Belyaeva
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
N. F. Smirnova
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
Т. G. Alekseeva
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
М. V. Pashchenkov
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
В. Skurkovich
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
D. Kelly
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	United States, 							Moscow; Rockville, USA						
S. V. Skurkovic
Russian State Medical University; ABC Labs
														Email: info@eco-vector.com
				                					                																			                												                	Russian Federation, 							Moscow; Rockville, USA						
References
- Гусев Е.И., Демина Т.Л., Бойко А.Н., Татаринова М.Ю. // Журн. невропатол. и психиатр.—1992.—№ 2.—С. 14—18.
 - Arnason B.G.W., Reder А.Т. // Clin. Neuropharmacol.— 1994—Vol.17 .—P.495—547.
 - Goodkin D.E. // West J. Med.—1994.—Vol.161.— P.292—298.
 - Gusev E.I., Demina T.L., Boiko A.N., Pinegin B.V. // J. Neurol.—1994.—Vol.241—P.500—510.
 - Gusev E.I., Demina T.L., Boiko A.N., Favorova 0.0. In: Milonas I (ed). Proceedings of the 10th ECTRIMS Congress.—University Studio Press, Thessaloniki, Greece, 1995.—P.201—203.
 - IFNB Multiple Sclerosis Study Group, the University of British Columbia, MS/MRI Analisis Group. Interferon betalb in the treatment of MS: final outcome of the randomized controlled trial.—Neurology.—1995.—Vol.45.—P.1277—1285.
 - Jacobs L., Cookfair D.L., Rudick R.A. et al. // Ann. Neurol.—1996.—Vol.39—P.285—294.
 - Kahan B.D. // J. Med.—1989.—Vol.321.—P.1725—1739.
 - Khoury S.J., Weiner H.L., Hafler D.A. In: Cook S (ed). Handbook of multiple sclerosis.—N.-Y., 1990.—P.129—150.
 - Kirk J. // J.Neuroimmunol.—1991.—Vol.32.—P.87—94.
 - McFarlin D.E. // Ann. Allergy.—1990.—Vol.64.— P.433—444.
 - Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial.—Ann. Neurol.—1990.—Vol.27.—P.591—605.
 - Poser C.M., Paty D.W., Scheinberg L. et al. // Ann. Neurol.— Vol. 13.—P.227—231.
 - Ruddle N.H., Beyman C.M., McGrath M.L. et al. // J. Exp. Med. —1990.—Vol. 172.—P. 1193—1200.
 - Selmaj K., Rain C.S. // Ann. Neurol.—1991—Vol.30.- P.694—700.
 - The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis // Lancet.— 1991.—Vol.337.—P.441—446.
 - Weiner H.L., Ellison G.W. // Arch. Neurol.—1983.— Vol.40.—P.704—710.
 - Whitaker LN. // Ann. Neurol.—1994.—Vol.36.- P.103—107.
 
Supplementary files
				
			
					
						
				

